Menu

Horizon Discovery extends CRISPR Screening Service to primary human T cells

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.

Jan 21, 2019
Horizon Discovery

CRISPR screens in primary T lymphocytes have proved challenging, owing to complex issues around the introduction of the screening components and Cas9 in particular. Horizon has adapted its established CRISPRko (knockout) platform to address these issues and to deliver a robust screening platform in human T lymphocytes, which will enable complex biological processes, novel targets and more effective drug therapies to be investigated in a therapeutically relevant cell type.

Horizon has added CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The Company’s extension of its CRISPRko Screening Service strengthens its existing immuno-oncology platform and reinforces its commitment to supporting researchers working in this rapidly growing field of research.

Terry Pizzie, Chief Executive Officer, Horizon Discovery Group,commented:“The successful demonstration of primary human T cells in Horizon’s CRISPR screening platforms is a breakthrough format for our clients working in the immuno-oncology space; enabling them to find gene targets and potential therapeutic avenues in an immediately biologically relevant setting rather than having to work through surrogate cell lines. We expect that this approach will allow our customers to save considerable time and resources in downstream validation, helping them to get therapeutics to the clinic faster.”


For more information about Horizon’s most recent T cell screen please visit: https://dharmacon.horizondiscovery.com/resources/featured-articles/lentiviral-sgrna-crispr-screening-t-cells/

For more information about Horizon’s CRISPR Screening Service please visit: https://www.horizondiscovery.com/research-services/functional-genomic-screening/crispr-screening

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Handbook of Assays for Developing Targeting Therapeutics
Handbook of Assays for Developing Targeting Therapeutics
Download this handbook from LI-COR Biosciences to learn about key assays used to answer vital questions related to therapeutics research, including Western blotting, protein profiling, tissue section microscopy, and in vivo and ex vivo imaging!
Why Less is More When it Comes to Ultra-Low Temperature Freezers
Why Less is More When it Comes to Ultra-Low Temperature Freezers
Download the latest application article to learn how replacing compressor-based ultra-low temperature freezers with more energy- and space-efficient Stirling Ultracold units delivers more overall cost savings while operating with a smaller carbon footprint.
Seven Tips to Improve Cell Counting Accuracy
Seven Tips to Improve Cell Counting Accuracy
Download this technical note to learn seven top tips to ensure accurate and reproducible results, whether counting cells manually or using automated systems!